Genomic Valley Biotech Ltd - 539206 - Certificate Pursuant To Regulation 40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed herewith the certificate pursuant to Regulation 40 (10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the ended on 31st March, 2022. Genomic Valley Biotech Ltd - 539206 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Hanuman PrasadDesignation :- Company Secretary and Compliance Officer Genomic Valley Biotech Ltd - 539206 - Submission Of Compliance Certificate Pursuant To Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed herewith the Compliance Certificate pursuant to Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on 31st March, 2022. Genomic Valley Biotech Ltd - 539206 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith the certificate pursuant to Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended on 31st March, 2022. Genomic Valley Biotech Ltd - 539206 - Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
With reference to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, the Company is in receipt of Annual Disclosure from Promoters together with the Person Acting in Concert (PAC), for the financial year ended 31st March 2022. As disclosure received from Promoters together with the Person Acting in Concert (PAC) is enclosed herewith for your reference and records. Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window
Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI(Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons shall remain closed from April 01, 2022 till 48 (Forty Eight) hours after the conclusion of the Meeting of the Board of Directors of the Company to be held to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2022. The date and venue of Board Meeting for the aforesaid purpose shall be intimated to you in due course. Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Newspaper advertisements of the Extract of Un-Audited Financial Results for the quarter ended 31.12.2021 and year to date from 01.04.2021 to 31.12.2021 approved in Board Meeting of the Company held on 12.02.2022. Genomic Valley Biotech Ltd - 539206 - Revised Policy On Related Party Transactions
The Company has revised Policy on Related Party Transactions which is available on the Company's Website, www.genomicvalley.com . Genomic Valley Biotech Ltd - 539206 - Intimation Of Appointments
1. Pursuant to the Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 issued by Securities and Exchange Board of India and other applicable provisions thereto, if any, the Board of Directors, in its meeting held today, has approved the appointment of Rohit Batham & Associates, Practicing Company Secretaries, with immediate effect to issue Annual Secretarial Compliance Report for the Financial Year 2021-22. 2. Pursuant to the Regulation 76 of SEBI (Depositories and Participants) Regulations, 1996 and any other provision applicable thereto, if any, the Board of Directors, in its meeting held today, has approved the appointment of ANDROS & CO., Chartered Accountants, with immediate effect to issue Reconciliation of Share Capital Audit Report on quarterly basis for the Financial Year 2022-23. Genomic Valley Biotech Ltd - 539206 - Submission Of Outcomes Of Board Meeting And Un-Audited Financial Results For The Quarter Ended 31.12.2021 And Year To Date From 01.04.2021 To 31.12. 2021
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Un-Audited Financial Results (Standalone) of the Company for the Quarter ended 31.12.2021 and year to date from 01.04.2021 to 31.12.2021 as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.